Autologous graft-versus-host disease

International Journal of Hematology

Volumn 65, Issue 2, 1997, Pages 105-113

  Karasuno, Takahiro ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

AutoBMT; AutoGvHD; Cyclosporine A

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TACROLIMUS;

ARTICLE; AUTOGRAFT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HUMAN; PRIORITY JOURNAL;

EID: 0031081535     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(96)00541-5     Document Type: Article

References (62)

1. [1] Morishima Y, Kodera Y, Hirabayashi N et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible sibling; possible role of genetic homogeneity. Blood 1989;74:2252-2256.
2. [2] Morishima Y, Kodera Y, Hirabayashi N et al. Low incidence of acute GvHD in patients transplanted with marrow from HLA-A. B. DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 1995;15:235-239.
3. [3] Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effects of graft-versus-host disease in human recipients of allogeneic-marrow graft. N Engl J Med 1979;300:1068-1073.
4. [4] Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1980;304:1529-1533.
5. [5] Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
6. [6] Rappeport J, Mihm M, Reinherz E et al. Acute graft-versus-host disease in recipients of bone marrow transplants from identical donors. Lancet 1979:Oct. 6:717-720.
7. [7] Einsele H, Ehnigner G, Schneider EM et al. High frequency of graft-versus-host-like syndromes following syngeneic bone marrow transplantation. Transplantation 1988;45:579-585.
8. [8] Hood AF, Vogelsang GB, Black LP et al. Acute graft-vs-host disease. Arch Dermatol 1987;123:745-750.
9. [9] Gluckman E, Devergie A, Sohier J et al. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet 1980;Feb 2:253-254.
10. [10] Glazier A, Tutschka PJ, Farmer ER et al. Graft-versus-host disease in cyclosporine A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983;158:1-8.
11. [11] Jones RJ, Vogelsang GB, Hess AD et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989;8:754-757.
12. [12] Hess AD, Horwitz L, Beschorner WE et al. Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. J Exp Med 1985;161:718-730.
13. [13] Hess AD, Horwitz LR, Laulis MK. Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo. Transplant Proc 1993:25:1218-1221.
14. [14] Lillehoj HE, Malek TR, Shevach EM et al. Differential effect of cyclosporin-A on the expression of T and B lymphocyte activation agents. J Immunol 1984:133:244-250.
15. [15] Helin HJ, Edgington TS. Cyclosporin-A regulates monocyte macrophage effector functions by affecting instructor T cells: inhibition of monocyte procoagulant response to allogeneic stimulation. J Immunol 1984;132:1074-1076.
16. [16] Tutschka PJ, Hess AD, Beschorner WE. Cyclosporine in clinical marrow transplantation: the Baltimore experience. Transplant Proc 1983;15:2613-2616.
17. [17] Sorokin R, Kimura H, Schroder K et al. Cyclosporine-induced autoimmunity. J Exp Med 1986;164:1615-1625.
18. [18] Kosugi A, Sharrow SO, Shearer GM. Effect of cyclosporine A on lymphopoiesis. I. Absence of mature T cells in thymus and periphery of bone marrow transplanted mice treated with cyclosporin. J Immunol 1989;142:3026-3032.
19. [19] Glazier A, Tutschka PK, Farmer ER. Studies on the immunobiology of syngeneic and autologous graft-versus-host disease in cyclosporine-treated rats. Transplant Proc 1983;15:3035-3041.
20. [20] Cheney RT, Sprent J. Capacity of cyclosporine to induce auto-graft-versus-host disease and impair intrathymic T cell differentiation. Transplant Proc 1985;17:528-530.
21. [21] Beschorner WE, Di gennaro KA, Hess AD et al. Cyclosporine and thymus: influence of irradiation and age on thymic immunopathology and recovery. Cell Immunol 1987;110:350-364.
22. [22] Jenkins MK, Schwartz RH, Pardoll DM et al. Effect of cyclosporine A on T cell development and clonal deletion. Science 1988;241:1655-1658.
23. [23] Gao E-K, Lo D, Cheney R et al. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336:176-179.
24. [24] Kosugi A, Zuniga-Pflucker JC, Sharrow SO et al. Effect of cyclosporin A on lymphopoiesis. II. Developmental defects of immature and mature thymocytes in fetal thymus organ cultures treated with cyclosporin A. J Immunol 1989;143:3134-3140.
25. [25] Siegel RM, Yui MK, Tenenholz DE et al. Inhibition of development in thymic organ culture: implications for the mechanism of action of cyclosporin A. Eur J Immunol 1990;20:753-757.
26. [26] Hess AD, Vogelsang GB, Heyd J et al. Cyclosponne-induced syngeneic graft-versus-host disease: assessment of T cell differentiation. Transplant Proc 1987;19:2683-2686.
27. [27] Kappler JW, Roehm N, Marrck P et al. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273-280.
28. [28] Bruner K, Opitz HG, Kolsch E et al. The thymus as primary site for antigen-specific T suppressor cells in neonatally induced tolerance to bovine serum albumin. Immunobiology 1982;162:221-228.
29. [29] Fischer AC, Laulis MK, Horwitz L et al. Host resistance to cyclosporine induced syngeneic graft-versus-host disease. J Immunol 1989;143:827-832.
30. [30] Hess AD, Fischer AC. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989;48:895-900.
31. [31] Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994;84:2061 2067.
32. [32] Shi Y, Sahai BM, Green DR. Cyclosponn A inhibits activation induced cell death in T cell hybridomas and thymocytes. Nature 1989;339:625-626.
33. [33] Fischer AC, Beschorner WE, Hes AD. Requirement for the induction and adoptive transfer of cyclosporine-induced graft-versus-host disease. J Exp Med 1989;169:1031-1041.
34. [34] Hess AD, Horwitz L, Laulis MK et al. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol 1993;69:341-350.
35. [35] Geller R, Esa AH, Beschorner WE et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989;74:1165-1171.
36. [36] Urdahl KB, Pardoll DM, Jenkins MC et al. Self-reactive T cells are present in the peripheral lymphoid tissues of cyclosporin A-treated mice. Int Immunol 1992;4:1341-1349.
37. [37] Bryson JS, Lake-Bullock H, Pflugh DL et al. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995;60:171-178.
38. [38] Hess AD, Fischer AC, Beschorner WE. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. J Immunol 1990;145:526-533.
39. [39] Bucy RP, Xu XY, Li J et al. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993;151:1039-1050.
40. [40] Fischer AC, Ruvolo PP, Burt R et al. Characterization of autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1995; 154:3713-3725.
41. [41] Hess AD, Fischer AC, Horwitz L et al. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994;153:400-411.
42. [42] Noga SJ, Horwitz L, Kim H et al. Interferon-γ potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992;1:75-84.
43. [43] Hess AD, Noga SJ. Cyclosporine induced syngeneic graft-versus-host disease: an immunotherapeutic approach after autologous bone marrow transplantation. Int J Cell Cloning 1992;10(Suppl 1): 179-181.
44. [44] Talbot DC, Powles RL, Sloane JP et al. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia. Bone Marrow Transplant 1990;6:17-20.
45. [45] Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992;79:3031-3035.
46. [46] Karasuno T, Nakamura H, Fukuda H et al. Induction of autologous graft-versus-host disease in autologous bone marrow transplantation. The 4th CAST 1995;325.
47. + cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;13:181-185.
48. [48] Dolei A, Capobianchi MR, Ameglio F. Human γ-interferon enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than χ-interferon and β-interferon. Infect Immun 1983;40:172-176.
49. [49] Kennedy MJ, Vogelsang GB, Jones RJ et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994;12:249-257.
50. [50] Ratanatharathorn V, Uberti J, Karanes C et al. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 1994;13:625-630.
51. [51] Costello R, Blaise D, Jacquemier J et al. Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation. Bone Marrow Transplant 1995;16:199-200.
52. [52] Higuchi CM, Thompson JA, Thomas Cox et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989;49:5509-5513.
53. [53] Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990;76:1092-1097.
54. [54] Mackinnon S, Hows JM, Goldman JM et al. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990;76:2037-2045.
55. [55] Hauch M, Gazzola MV, Small T et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990;75:2250-2262.
56. [56] Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992;79:517-526.
57. [57] Charak BS, Brynes RK, Chogyoji M et al. Lymphokine-activated killer cells in autologous bone marrow transplantation. Transplantation 1992;54:1008-1013.
58. [58] Charak BS, Agah R, Mazumder A. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 1992;80:179-184.
59. [59] Dale BM, Atkinson K, Kotasek D et al. Cyclosporine-induced graft vs host disease in two patients receiving syngeneic bone marrow transplants. Transplant Proc 1989;21:3816-3817.
60. [60] Caralla AM, Gaozza E, Piatti G et al. Induction of graft versus host disease (GvHD) after ABMT for high risk ALL in first CR and second chronic phase of chronic myeloid leukemia. Exp Hematol 1990;18: 684.
61. [61] Jones RJ, Vogelsang GB, Ambinder RF et al. Autologous bone marrow transplantation (ABMT) with cyclosporine (CSA)-induced autologous graft-versus-host disease (GvHD) for relapsed aggressive non-Hodgkin's lymphoma (NHL). Blood 1991:78:287a.
62. [62] Carella AM, Gaozza E, Congiu A et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 1991;62:156-159.